Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Almirall, S.A.
  6. News
  7. Summary
    ALM   ES0157097017

ALMIRALL, S.A.

(ALM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Almirall S A : net profit falls 39% in Q1 as it looks for M&A opportunities

05/10/2021 | 02:08am EDT

BARCELONA, May 10 (Reuters) - Spanish pharmaceuticals group Almirall said on Monday its first-quarter net profit fell 38.7% to 29.8 million euros ($36.2 million) and revenues by 10%, as the company looks for merger and acquisition (M&A) opportunities.

The Barcelona-based firm continued to be hurt by the pandemic as mobility restrictions led to fewer patients going to the doctor, while sales suffered from generic competition in the United States.

It said on Monday it predicts COVID-19 will continue to affect its operations in the first half, before its impact lessens in the second half of the year.

With Gianfranco Nazzi recently sworn as chief executive after leaving Israel's Teva Pharmaceuticals Industries, Almirall said it would look for external opportunities that would strengthen its main business and presence in key markets.

"The solid results in 2020 and 2021's first quarter confirm that we are on the right track and strengthen our position in medical dermatology," Nazzi said in a statement.

He said the company would invest in new products to achieve mid-term growth.

Chairman Jorge Gallardo said on Friday Almirall was looking for new dermatology opportunities in the United States.

It reiterated its 2021 guidance for mid-single digit percentage growth in core sales, and for earnings before interest, tax, depreciation and amortization (EBITDA) of 190 million to 210 million euros, up from 181 million euros in 2020.

EBITDA fell 16% in the first quarter to 74.2 million euros, while total revenue reached 222.5 million euros, higher than had been expected by analysts polled by Refinitiv.

Its first-quarter net profit decline was steeper than the 29.9% registered in 2020. Financial debt had increased slightly since end 2020, to 475.8 million euro.

($1 = 0.8229 euros) (Reporting by Joan Faus; Editing by Inti Landauro and Jan Harvey)


© Reuters 2021
All news about ALMIRALL, S.A.
06/20MAYNE PHARMA  : Adds New Products to Australian Dermatology Portfolio
MT
06/17ALMIRALL S A  : joins BIOMAP as a new partner to advance the field of inflammato..
PU
06/11ALMIRALL S A  : appoints Dr. Karl Ziegelbauer as Chief Scientific Officer
PU
06/01ALMIRALL S A  : receives FDA approval to produce Seysara ® (sarecycline) at the ..
PU
05/26UK pharma group Vectura agrees $1.4 billion takeover by Carlyle
RE
05/26UK pharma group Vectura agrees $1.4 bln takeover by Carlyle
RE
05/21ATHENEX  : Receives Positive Opinion From European Medicines Agency on Klisyri t..
MT
05/21ATHENEX  : Klisyri Receives Positive Opinion From European Medicines Agency to T..
MT
05/21ALMIRALL S A  : Gets EMA's Positive Opinion For Klisyri To Treat Skin Disease
MT
05/21ALMIRALL S A  : receives positive CHMP opinion for Klisyri®▼ (tirbanibulin..
PU
More news
Financials
Sales 2021 834 M 995 M 995 M
Net income 2021 84,7 M 101 M 101 M
Net Debt 2021 300 M 357 M 357 M
P/E ratio 2021 32,3x
Yield 2021 1,24%
Capitalization 2 616 M 3 114 M 3 120 M
EV / Sales 2021 3,49x
EV / Sales 2022 3,19x
Nbr of Employees 1 787
Free-Float 40,7%
Chart ALMIRALL, S.A.
Duration : Period :
Almirall, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALMIRALL, S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 14,55 €
Average target price 15,71 €
Spread / Average Target 7,98%
EPS Revisions
Managers and Directors
NameTitle
Gianfranco Nazzi Chief Executive Officer & Executive Director
Michael McClellan Chief Financial Officer
Jorge Gallardo Ballart Chairman
Bhushan D. Hardas Chief Scientific Officer
Volker Koscielny Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL, S.A.33.24%3 097
JOHNSON & JOHNSON3.96%431 456
ROCHE HOLDING AG12.99%328 650
PFIZER, INC.7.61%220 661
NOVARTIS AG3.00%210 615
ABBVIE INC.7.05%202 639